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ABSTRACT
The lack of resolution and selectivity in current imagining techniques such as xray, optical, and magnetic resonance imaging (MRI) has excelled the development of
new biosensor technologies. Cryptophane A, a molecular cage composed of two
cyclotriveratrylene (CTV) units connected by alkoxy bonds, can be turned into
biosensors by attaching a target moiety capable of binding to a particular analyte.
Cryptophanes can encapsulate xenon making it an attractive biosensor candidate for
detection by hyperpolarized xenon-129 (HP-129Xe) MRI. Further detection
enhancement is achieved by using a technique called hyperpolarized chemical exchange
saturation transfer (HYPER-CEST). One of the key challenges in developing Xebiosensors is the need for water soluble cryptophanes and their attachment to
biomolecules that specifically bind physiological targets.
The first manuscript entitled “Functionalization of Cryptophane cages for Xenon
MRI” discusses the synthesis of cryptophane cages and their potential to be further
functionalized. The manuscript centers on synthesizing cryptophanes that are water
soluble functionalized with gold nanoparticles, which can eventually be further
modified for imaging molecular events in vivo.
The second manuscript, “Vanadium Catalyzed Oxidative Coupling of sp3 C-H
Bonds to Heteroarenes” discusses oxidative aminomethyaltion of imdizolpyridines.
This manuscript proposes a vanadium catalyzed oxidative coupling of imidazopyridines
with N-methylmorpholine oxide which serves as both sp3 hybridized coupling partner
and the oxidant. The reaction was optimized and performed with a variety of substrates

to yield on a library of aminomethylated products. We investigated the mechanism and
propose that a Mannich-type mechanism is responsible for the formation of the product.
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PREFACE
The following work is presented in manuscript format according to the
guidelines presented by the University of Rhode Island Graduate School. This thesis
will consist of two manuscripts that are currently in the process of publication.
Manuscript 1 entitiled, “Functionalization of Cryptophane Cages for

129

Xe

MRI” will be submitted to Bioorganic and Medicinal Chemistry Letters in December
2014.
Manuscript 2 entitled, “Vanadium Catalyzed Oxidative Coupling of sp3 C–H
Bonds to Heteroarenes” will be submitted to Organic Letters for publication in
November 2014.
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INTRODUCTION

The ability to make a definitive medical diagnosis and follow the onset of certain
diseases is vital in treating patients. Current imaging techniques, such as CT, PET, and
MRI, possess different limitations that lower their overall effectiveness (Table 1). 1
Computed tomography, a non-invasive imaging method, generates an image by using
X-rays that are absorbed by tissues.2 Though inexpensive, CT is incapable of molecular
imaging and exposure to hazardous X-ray radiation renders CT a less attractive method
for imaging. Positron emission tomography (PET) and single photon emission
computed tomography (SPECT) are capable of anatomical and molecular imaging.
These techniques are advantageous as there are no depth detection limits, short temporal
resolutions, no perturbation of biological systems, and they require very low doses of
the probe molecules.

However, both techniques lack spatial resolution, require

exposure to harmful radiation and are very costly.1
Imaging
Image
Spatial
Technique generation Resolution
X-rays
50-200
CT
mm
γ-rays
1-2 mm
PET
SPECT
MRI

γ-rays

1-2 mm

Temporal
resolution
10 secs to
mins
Minutes
Minutes

Type of
probe used
N.A.

Principal
Use
Anatomical

Radio
labeled
Radio
labeled
Paramagnetic

Gene
expression
Gene
expression
Physiological,
anatomical

radiowaves 50-500
Minutes
mm
to hours
Table 1: Characteristics of different imaging techniques1

Magnetic resonance imaging (MRI) is widely used for scanning deep tissue in
the diagnosis of human diseases. Though this technique allows for high spatial
resolution, only a small percentage of hydrogen nuclei align with the magnetic field,
rendering this technique inherently insensitive. To increase signal intensity, contrast
1

agents, such as gadolinium or iron oxide-based particles are often employed. These
contrast agents work by changing the T1 and T2 relaxation times of water, thereby
enhancing signal intensity.3 However, recent findings suggest that development of
nephrogenic systemic fibrosis (NSF) in patients can be triggered by the administration
of gadolinium agents.4 Other MRI contrast agents such as manganese and lanthanides,
are toxic even at low concentrations and interfere with neuronal functions by blocking
ion-channels.5 As a result, the need for non-toxic and non-proton MRI contrast agents
needs to be explored. These issues may be circumvented by incorporating the inert noble
gas xenon-129 (129Xe) as a molecular probe, since it is not present in the body, it is nontoxic, and it can be hyperpolarized to enhance its sensitivity. Herein, the use of xenon129 in MRI, its ability to be hyperpolarized, Hyper-CEST techniques that allow for
better detection, and the utilization of water soluble cryptophanes as hosts for Xe will
be discussed.
Hyperpolarized Xenon
Xe exists as two NMR active isotopes, a spin-1/2 nucleus
nucleus

131

129

Xe and spin-3/2

Xe. Only the former is capable of being hyperpolarized.6 The ability to

hyperpolarize 129Xe is advantageous, as it allows for a 10,000-times signal enhancement
as a result of the alignment of more nuclear spins with the magnetic field. Where typical
proton MRI has only a 15 ppm chemical shift range,

129

Xe has range over 200 ppm,

which allows for chemical shift imaging.7 Solubility of xenon in lipid-rich tissue and
blood allows for imaging of brain, lung and other regions.8
Spin exchange optical pumping (SEOP) is a three-step process used to
hyperpolarize 129Xe. The first step involves the generation of circular polarized light by
2

a Ti:sapphire laser (Figure 2). In the second step, a droplet of Rb is heated in a glass
cell, while exposed to a magnetic field, to produce a vapor, which then absorbs circular
polarized light, driving the selective excitation of the D1 transition state. The third step
produces hyperpolarized 129Xe. When polarized Rb collides with 129Xe, it transfers the
spin of its valence electron to the 129 Xe nucleus. As a result of this dipole interaction,
xenon is now predominately in the state that is aligned with the external magnetic field.
9

Once hyperpolarized (HP) 129Xe is achieved, it can be delivered in vivo to be imagined.

Figure 1: SEOP set up 9
The delivery of HP -129Xe to the body can be achieved through inhalation or
injection. Inhalation of hyperpolarized 129Xe permeates through lung tissue and blood,
allowing for exploration of certain high concentration of characteristics of lung
3

function.10 Studies have shown that inhalation of HP- 129Xe results in highly spatially
resolved images (Figure 2). Typical 1H MRI is not a viable option for evaluation of
patients with chronic obstructive lung disease (COPD) or asthma as it is not capable of
imaging lungs, due to their low proton density (Figure 2 left). While using HP-129 Xe
in MRI yields an image that allows for distinction between lung airspaces in patients
with COPD and asthma, rendering HP-129Xe superior to 1H MRI. 11

Figure 2: MRIs of a subject with COPD and asthma, left: 1H MRI, right: HP-129Xe
MRI. 11
The polarization lifetime of 129Xe is dependent on its molecular environment.
In oxygenated blood T1 = 13 s, deoxygenated blood T1 = 4 s, and T1 ≈ 100 s in deuterated
saline solution.6 While long polarization lifetimes are advantageous, they require longer
time for imaging, which still does not result in optimal detection. Use of a host for 129Xe
allows for targeted imaging of molecular events. Such targeted molecular imaging via

4

129

Xe MRI is usually accomplished by employing molecular probes that contain cage-

shaped structures that are capable of encapsulating xenon atoms. The most common
molecular cage that is used for this task is called cryptophane A.
Cryptophanes
Cryptophanes are molecular cages composed of two cyclotriveratrylenes
(CTVs) that are connected by alkoxy linkers (Figure 3).12 The lipophilic character of
cryptophane’s cavity allows for reversible binding of small, non-polar molecules, like
xenon.

Figure 3: a) Cryptophane A, b) cryptophane 3,3,3, c) cryptophane 1,1,1, d)
cryptophane TAAC, and TTPC.11,13, 14
The affinity and exchange rate of xenon depends on the cavity size of the
cryptophane, which is varied by changing the number of carbons in the alkoxy linkers
that join the two CTVs (Table 2). As the cavity size of cryptophanes decreases, there
is an increase in the xenon binding constant.15 While large binding constants are
advantageous, the development of new detection techniques require the in and out
exchange to be fast, and therefore, 129Xe should not be so tightly bound.9
5

Cryptophane
(1.1.1)
A (2,2,2)
E (3,3,3)
TAAC A (2.2.2)
TTPC

Cavity Size
Binding constant kin (s-1)
(Å3)
(M-1)
81
10,000
n.d
95
3900
50
121
10
n.d
95
17,300
n.d
n.d
33,000
n.d
11,12,13
Table 2: Properties of cryptophanes

kout (s-1)
2.4
25
n.d
n.d
n.d

When 129Xe is bound in the cavity of a cryptophane cage, it produces a unique
chemical shift distinct from free 129Xe in the 129Xe NMR spectra. The typical chemical
shift of Xe@cryptophane complexes is demonstrated in Figure 4, where the larger the
cavity size, the more the peak corresponding to encapsulated 129Xe is shifted up-field.6
This trend is broken by Xe@cryptophane-1,1,1 with a chemical shift of 31.1 ppm,
whereas cryptophane A is at 65 ppm. It has been postulated this anomalous result is
derived from the absence of methoxy groups, which suggests that modifying cages
with electron withdrawing or donating groups can alter the chemical shift of
Xe@cryptophanes. 6 Functionalizing cryptophanes with water solublizing groups,
which are necessary for use in vivo, results in a higher binding affinity of 129Xe (Table
2).13,15

6

Figure 4: 129Xe NMR spectra of water soluble cryptophanes 16
One of the most promising applications of cryptophanes that encapsulate xenon
is their ability create biosensors. This can be achieved by conjugating cryptophanes to
a targeting ligand, which is capable of binding to a specific biological target, such as
receptors on tumors or sites of inflammation. For example, Dmoschowiski recently
synthesized a cryptophane that was tethered to the carbonic anhydrase (CA)-specific
ligand, benzenesulfonamide.17 When the benzensulfanamide cryptophane binds to CA
isozomes I or II, it produces a distinctive chemical shift from the biosensor when it is
free in solution.6

Despite the synthesis of new water-soluble and ligand-ligand-

functionalized cryptophanes, more sensitive techniques for detection of HP- 129Xe needs
to be addressed.

7

Hyper-CEST
Despite the high affinity of cryptophanes to bind

129

Xe, long acquisition times

are necessary to achieve well-resolved spectra of bound

129

Xe. This issue is

circumvented by incorporating a method called chemical exchange saturation transfer
(CEST) to enhance detection of hyperpolarized

129

Xe, when used in conjunction with

hyperpolarized 129Xe this technique is called Hyper-CEST. Xenon is an ideal candidate
for this method due to its long relaxation times and large chemical shift difference
between bound and free 129Xe.14
129

Instead of directly detecting the
HyperCEST detects the depletion of free

129

Xe that is bound in a cryptophane,

Xe. In order to do this, an off- and on-

resonance spectra is acquired. The off-resonance spectrum is a reference spectra
obtained by applying a continuous wave saturation (Figure 5 A). The on-resonance
spectrum is obtained by applying a radio frequency pulse tuned to

129

Xe@cryptopane

signal (Figure 5 B).18 The difference of the on and off resonance spectra results in signal
only arising from the depletion of the free

129

Xe peak.19 The exchange of

129

inside to outside the cryptophanes results in a reduction of the free 129Xe peak.

8

Xe from

Figure 5: Depiction of Hyper-CEST: a) off -resonance spectra b) on-resonance
spectra (modified from ref 18)18
When hyperpolarized

129

Xe (GREEN) enters the cage a radio frequency pulse

pre-saturates the bound xenon causing removal of polarization (RED) (Figure 6).17 The
depolarized 129Xe is then replaced by another polarized 129Xe atom through the natural
in and out exchange. This cycle continues until there is an accumulation of depolarized
129

Xe.

9

Figure 6: Hyper-CEST process 17

Dmochowski applied this technique to detect a water soluble cryptophane
(Figure 3D) at concentrations as low as 1.4 pM.20 This indicates that HyperCEST
should be an effective method for molecular imaging, as its detection limits are similar
to those of PET and SPECT. HyperCEST has recently been applied to multi-channel
detection of cryptophane-A and perfluoroctyl bromide nanodroplets as they both act as
hosts for 129Xe.18

10
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MANUSCRIPT 1

Efforts Towards Cryptophanes Functionalized with AuNPs
Abstract
While advances in imaging have made it possible for the diagnosis of certain
diseases, there are still many drawbacks. This paper aims to discuss the use of
hyperpolarized xenon in conjunction with gold nanoparticles that are decorated with as
a novel probe for magnetic resonance imaging (MRI). The synthesis of cryptophanes,
optimization of click reactions, and addition of gold nanoparticles will be discussed.
General Introduction
While conventional magnetic resonance imaging (MRI) allows for anatomical
imaging, it is inherently insensitive due to the minimal amount of protons capable of
aligning with the instrument’s magnetic field. Minimization of the signal to noise issues
that are inherent in 1H MRI, can be achieved by using 129Xe as a molecular probe, as it
is not present in the body and has the ability to be hyperpolarized, thereby giving a
10,000-times stronger signal.1 When

129

Xe is encapsulated by a porous cage-shaped

molecule, such as a cryptophane, a new signal, which is well resolved from the chemical
shift of free

129

Xe, is produced in the

129

Xe NMR spectrum. In principle, magnetic

resonance imaging techniques can translate this unique signal into a high-resolution 3D
image. If these cryptophanes are attached to target-specific ligands, the cryptophane
could serve as a biosensor, where its unique signal would be localized at a specific site
within the body. This cryptophane-ligand biosensor will allow for the specific detection
of molecular processes or receptors.

15

Using hyperpolarized chemical exchange saturation transfer (HyperCEST)
provides another source of signal amplification allowing for detection of submicromolar concentrations of physiological targets. By selectively irradiating the 129Xecryptophane signal, the loss of magnetization of the larger bulk Xe peak is easily
detected. This indirect detection method allows for very low detection limits, indicating
that HyperCEST imaging could be used for true molecular imaging.1 Cryptophanes can
be synthesized into biosensors by functionalizing cryptophanes with antibodies or
peptide ligands that are capable of binding to specific targets in the body, such as
enzymes. By doing this they are capable of being delivered to human cells and achieving
concentrations that would allow for in vivo hyperpolarized 129Xe MRI studies. 2 Recent
HyperCEST NMR experiments of water soluble triacetic acid cryptophane A have
shown depolarization of

129

Xe at a rate of 1.2x104 HP

129

Xe atoms per second.3 This

sensitive detection was performed at picomolar concentrations–a huge improvement
over previous work at micromolar concentrations.
Selective biosensors can be synthesized by functionalizing cryptophanes with
antibodies or peptide ligands that are capable of binding to specific targets in the body,
such as genes, receptors or enzymes. When the ligands on the biosensor bind to a
specific target, a unique signal is produced allowing for detection of molecular events
making it ideal for in vivo hyperpolarized 129Xe MRI studies. 2, 4
Gold nanoparticles (AuNPs) are capable of being functionalized with a myriad
of organic or biological ligands that bind selectively to small molecules or biological
targets. This is achieved by varying the type of capping ligand used and fast or slow
addition of NaBH4.5 The use of gold nanoparticles in imaging has grown over the years

16

due to their unique optical properties. Along with the use of gold nanoparticles for
various modes of imaging, they can be also used for drug delivery.7 For instance, Kim
et al., developed multifunctional gold nanoparticles capable of anticancer therapy and
computed tomography (CT) imaging of cancer cells.8 Further benefits of using gold
nanoparticles is that they are nontoxic and non-immunogenic making them ideal drug
delivery scaffolds.9 Therefore, tethering both cryptophanes and biological ligands to
gold nanoparticles would allow for targeted imagining via HP-129Xe MRI.

Scheme 1: Click reaction of cryptophane A to AuNPs (where n = # carbons)

The use of gold nanoparticles to facilitate drug delivery and imaging when
tethered to a cryptophane is unprecedented. The proposed study will focus on efforts
towards synthesizing a biosensor consisting of a cryptophane tethered to gold
nanoparticles via a thiol linker. The addition of protected thiol linkers to cryptophanes
will be accomplished via the copper-catalyzed Huisgen cycloaddition, the so-called
azide-alkyne click reaction (Scheme 1). After deprotection of the thiol group, gold
nanoparticles capped with thiol ligands will be added to AuNPs that have been
previously capped with labile thiol ligands. These thiols will undergo ligand exchange
with the thiols on the cryptophanes to yield the desired nanoparticles decorated with
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cryptophanes. The amount of cryptophane loaded onto the nanoparticle surface will be
quantified by infrared spectroscopy.
Cryptophanes and Gold Nanoparticles
Over recent years, AuNPs have become increasingly popular in imaging due to
their unique optical properties and ability to functionalize the surface with a myriad of
organic compounds or biological ligands that selectively bind small molecules or
biological targets.5 Additionally, gold nanoparticles are can be used as drug delivery
vehicles, as gold nanoparticles have been shown to be non-toxic. Browen et al., achieved
this by tethering the anti-cancer drug oxaliplatin to gold nanoparticles resulting in direct
site drug delivery.6
Tethering gadolinium (Gd) chelates to AuNPs has the capability to enhance the
contrast signal in 1H MRI images. This enhancement is a result of the large number of
Gd chelates on each AuNP, allowing for a more pronounced enhancement in contrast
near the site of the AuNps.7 However, as previously discussed, the toxicity of Gd
chelates renders them as less attractive modes of imaging. The capability to achieve
signal enhancement utilizing gold nanoparticles initiated our investigation into
developing AuNP-based 129Xe biosensors using a cryptophane.
As originally reported by Dmochowski, the tripropargyl cryptophane-2,2,2 (2
refers to the number of carbons in the alkoxy bridge between cage top and cage bottom),
derivative can be accomplished in ten steps.4 The top of the cage, 1.3, was synthesized
in three steps (Scheme 2). Vanily alcohol is protected with an allyl group in order to
avoid polymerization in the cyclization step (Scheme 2). Cyclization was achieved

18

through a Friedel-Crafts cyclization using HClO4 and MeOH. Deprotection of the allyl
group required excess amounts of Pd/C and TsOH.

Scheme 2: Synthesis of cage top

Though the number of carbons in the propargyl linker can be varied,
incorporating ethylene bridges results in a cryptophane cavity size that allows for
optimal binding and exchange of

129

Xe. Consequently, we set out to synthesize a

cryptophane cage containing ethylene bridges between the two cyclotriveratrylenes.
The linker containing the propargyl group was synthesized in five steps (Scheme 3).
The first step, selective addition of the propargyl linker to the 3-position the linker
starting material, 3,4 dihydroxybenzaldehyde was achieved using NaH and propargyl
bromide. Though both phenols are deprotonated, position 4 is stabilized through
resonance, therefore not as reactive as the 3 position (1.4). Subsequent steps included
the addition of an ethylene linker (1.5), reduction of the aldehyde (1.6), a Finkelstein
reaction (1.7) and finally, protection of the benzyl alcohol as a tetrahydropyranyl (THP)
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ether (1.8). This protection step was necessary to avoid any unwanted side products in
the final steps, and was easily removed in situ during the last step. Until recently, the
majority of the aforementioned reactions required purification using flash
chromatography, but we have recently developed recrystallization conditions that allow
for easier scale-up of these synthetic steps. Recrystalization using hexanes and minimal
amounts of ethyl acetate was implemented for the purification of 1.4, 1.5, and 1.6,
resulting in analytically pure product. Since there is more of a possibility for side
products during the first reaction, flash chromatography was kept as a purification
procedure for the first step. When using recrystallization for the second step, a 77%
yield was obtained, while using flash chromatography for the same step gave a 75%
yield. Recrystallization for the reduction step resulted in comparable yields to when
flash chromatography was used. Though similar yields were obtained, recrystallization
is less time consuming and requires less solvent, so it became our preferred purification
method.

Scheme 3: Synthesis of propargyl linker
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Once the linker was synthesized, it was added in excess to the cage top and
heated for two days under nitrogen at 55 ºC in the presence of the base, cesium carbonate
(Scheme 4, 1.9). The final step in the synthesis of the conjugatable cryptophane (1.10)
was the cyclization of the cage bottom, through a second Friedel-Crafts reaction,
mediated by perchloric acid (Scheme 4). The overall yield of this synthesis is rather low
due unwanted polymerization.

Scheme 4: Synthesis of tripropargyl cryptophane A
The conversion of tri-propargyl Cryptophane A to a biosensor can be achieved
via copper(I)-catalyzed Hugsien cycloaddition “click” of a targeting moiety.2 Our aim
was to decorate gold nanoparticles (AuNPs) with cryptophane cages, which potentially
could increase the cryptophanes’ water solubility improving their applicability for invivo imaging. Using gold nanoparticles also acts as a second scaffold to which
biological ligands could be tethered.
There are multitudes of ways to synthesize gold nanoparticles. For our purposes,
the Brust-Schiffron method was the most attractive, as the resulting tiol capped AuNPs
are easily re-dispersed in organic solvents, which we envisioned to be an advantage for
subsequent modification reactions. Additionally, the dodecanethiol capping ligand used
in the AuNP synthesis is known to readily undergo ligand exchange of a variety of
thiols.5, 8 Copper(I) catalyzed azide-alkyne cycloaddition (CuAAC), click chemistry,
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can be used to modify gold nanoparticles by employing an azide linker containing a
thiol group.9
The modification of AuNPs using click chemistry can be achieved via indirect
and direct pathways. The indirect method involves synthesizing AuNPs with a
dodecanethiol capping ligand that readily undergoes ligand exchange with a thiol-azide
linker. At this point click chemistry using the appropriate conditions can be carried out
between a cryptophane bearing alkyne groups, such as 1.10, and the azide-decorated
AuNP.9a.9a The direct method involves carrying out the click reaction with a protectedthiol-azide linker and a cryptophane like 1.10 in solution. Once completed, the thiol,
which is now tethered to the cryptophane, can be deprotected and added as a capping
ligand during the synthesis of AuNPs. Recent studies have found this method prevents
aggregation of the consequent AuNPs.9a As a result, our initial attempts employed this
method.
To carry out the click chemistry with the alkynes on cryptophanes, an azide-thiol
linker needed to be synthesized. We attempted the synthesis of two azide-thiol linkers
(Scheme 5). In order to avoid poisoning of the copper catalyst and unwanted side
products during the click reaction, the thiol group needed to be protected. This was
achieved using trityl chloride to protect 2-aminoethanelthiol (1.11, Scheme 5) and
acetate to protect mercaptopropionic acid (1.14). The synthesis of the azide portion of
the two possible linkers was carried out by refluxing 3-bromopropionic acid or 2bromoethylamine with sodium azide. Both reactions required extended reaction times
and, unfortunately, were low yielding. The synthesis of both azide-thiol linkers was
then achieved using peptide-coupling conditions.
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Scheme 5: Synthesis of protected thiol azide linkers.
Previous click conditions utilized by Dmochowski, which required Cu2SO4,
K2CO3, 2,6-lutidine and sodium ascorbic acid, did not result in any product and also are
not compatible with gold nanoparticles, as salts cause the aggregation of gold
nanoparticles.4 Therefore, new click conditions needed to be established and optimized.
To achieve optimal yields when carrying out the click reaction with cryptophanes, the
reaction was first optimized using the cryptophane linker, 1.5, with the thiol-azide
linkers.
Initially, copper sulfate pentahydrate and sodium ascorbic acid conditions were
applied to click the trityl-thiol-azide linker (1.13) to 1.5 and eventually to tripropargyl
cryptophane A, 1.10 (Scheme 4). Though yields were sufficient, the inability to
deprotect the trityl group after the click reaction, resulting in the need to switch to the
acetate protected thiol linker (1.16), in hopes that it would be easily deprotected.
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Originally, the same conditions for the previous click reaction were applied to
conjugate 1.16 to 1.5, however, no product was formed. It is possible that the bulky
trityl group on the thiol prevented the copper catalyst from coordinating with sulfur,
whereas the thioacetate group may not hinder the poisoning of the catalyst. New click
reactions involving copper(I) bromide [Cu(I)Br] and the hexabenzyltren (tren) ligand
turned out to give better yields than the previously described conditions. Due to the air
sensitivity of Cu(I)Br, these reactions were carried out in a Schlenk tube. The first
conditions applied were using 1 equivalent of the alkyne, 1.5, and 1.1 equivalents of the
azide, 1.16, with 30 mol% Cu(I)Br and the tren ligand, resulting in a 46% yield (Table
1). Decreasing the mole percentage of Cu(I)Br and tren actually led to an increase in
yield, though the reaction took 72 hr to complete. Optimal reaction conditions were
found to be 1 equivalent of 1.5, 1.1 equivalent of 1.16, 10 mol% Cu(I)Br and tren ligand
at 65 °C for 48 hr, giving a 64% yield (Table 1).

Table 1: Optimization click conditions

Entry

1.5
(equiv)

1.16
(equiv)

Cu(I)Br

1

1

1.1

30%

30%

2

1

1

10%

3

1

1.1

10%

Tren Ligand Solvent

Conditions

Yield

Toluene

60 °C
48 hr

46%

10%

Toluene

60 °C
72 hr

54%

10%

Toluene

65 °C
48 hr

64%

These optimal conditions were modified to achieve the click reaction at all three
alkynes on the cryptophane. This was achieved by using 40 mol% Cu(I)Br and 40% tren
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ligand. The solvent had to be changed from toluene, as cryptophane would not dissolve
in it, to THF. This allowed for a tri-subsituted cryptophane with acetate-protected thiol
linkers, 1.19, in a 59% yield (Scheme 6).

Scheme 6: Click pathways to sulfur functionalized cages
The next step involved deprotecting the acetate group. A multitude of different
conditions were applied. Initial attempts involved refluxing 1.19 for three hours in
hydrochloric acid and methanol. When this did not work, thionyl chloride and then
acetyl chloride conditions were applied. Neither of these worked and no starting
material was recovered, leading us to believe that the product decomposed. Basic
conditions were then applied, using ethanol and sodium hydroxide or potassium
hydroxide. This did not work for the products of the click reaction, but it did work for
the thioacetate linker (1.16). The inability to deprotect the thiol, which was needed to
25

carry out the previously discussed direct method of functionalizing AuNPs, led us to
explore the indirect method of AuNP functionalization.
As previously mentioned, the indirect method involved ligand exchange of the
dodecanethiol capping ligand with an thiol-azide chain. Deprotection of the trityl-thiolazide linker, 1.13, was achieved using TFA and triethylsilane in DCM. This was then
added to AuNPs in DCM and stirred for two days at room temperature. The solution
was concentrated and washed with ethanol to remove any free ligands. Successful
ligand exchange was verified by NMR (see supporting information). The click reaction
between the azide-tethered AuNPs and cryptophane was performed using Cu(I)Br and
the tren ligand. Unfortunately, the click reaction was not successful even with adding
excess amounts of catalyst and extended reaction times.
Another pathway to functionalize nanoparticles was attempted by performing
ligand exchange between dodecanethiol capping ligand and 11-bromoundecylthiol,
which was converted into an azide via an SN2 reaction with sodium azide. The formation
of the azide-decorated AuNPs was verified via NMR, allowing for click chemistry to be
carried out with tri-propargyl cryptophane using Cu(I)Br and tren ligand. While the
click reaction seemed to be successful, the AuNPs aggregated.
Conclusion
Future work involves using different deprotection strategies and/or protecting
groups. Additional routes for AuNP functionalization could be accomplished by
synthesizing a different cryptophane starting material by substituting one of the
propargyl linkers in the cryptophane for a linker that is functionalized with thiol group.
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Experimental Section
Reagents
All substrates and solvents were purchased from Sigma-Aldrich and Fisher Scientific.
Flash chromatography was performed using hand columns or a Teledyne ISCO
CombiFlashRf apparatus using RediSep Rf Silica gel (60 Å, 40-60 m).

Instrumentation
GC/MS analysis was carried out on an Agilent Technologies 6890 GC system fixed
with a 5973 mass selective detector. NMR spectra were acquired with a Bruker
Avance III 300 MHz spectrometer.

Compound 1.1: 3-methoxy-4-(2-propenyloxy) benzenemethanol:

Acetone, vanillyl alcohol (15.48 g, 97.29 mmol), and allyl bromide (12.94 g, 107.01
mmol) were added to round bottom flask and stirred until homogeneous. K2CO3 (13.44
g, 97.29 mmol) was added slowly and the mixture was refluxed overnight. The next
day, the reaction was cooled to room temperature while stirring. Acetone was then
removed under vacuum. The resulting white residue was dissolved in 50 mL of DCM
and 40 mL of H2O. The biphasic solution was transferred to a separatory funnel, and
the aqueous layer was removed, and the organic layer was washed with 1 M NaOH (3
x 50 mL) and brine (1 x 50 mL). The organic layer was collected, dried over MgSO4,
filtered and the solvent was removed under vacuum to yield a yellow powder. 50 mL
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of EtOAc was added, and then removed under vacuum (to remove excess allyl
bromide), resulting in 1.1 (15.54 g, 82%) as a fine white powder. All spectral
information matched literature values.1

Compound 1.2: 2,7,12-Trimethoxy-3,8,13-tris(2-propenyloxy)-10,15-dihydro-5Htribenzo cycloononene

In a round bottom flask equipped with a stir bar, 1.1 (4.91 g, 25.29 mmol) was
dissolved in methanol (36 mL) and cooled to 0 °C in an ice bath. Perchloric acid (15
mL) was added dropwise to the flask under N2. The solution turned magenta while it
stirred overnight. The following day, DCM was added to the solution, and it was
cooled again to 0 °C for 5 min. Then 32 mL of 5 M NaOH was added dropwise over
10 min followed by the dropwise addition of saturated NaHCO3 (32 mL). The reaction
was stirred at room temperature for 1-2 hours. The organic layer was then filtered,
dried with MgSO4 and concentrated. Diethyl ether was added and the resulting
suspension wad sonicated for 1 hr. The suspension was allowed to stir overnight at
room temperature. The thickened product was isolated by filtration and the solid was
dried under high vacuum to yield 1.2 (2.01 g, 15%) as an off -white solid. All spectral
information matched literature values.1

Compound 1.3
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In a round bottom 1.2 (3.36 g, 6.34 mmol) was dissolved in THF (100 mL) and EtOH
(68 mL) in a vacuum-dried flask under N2. In a separate round bottom flask Pd/C
(4.06 g, mmol) and TsOH (0.72 g, 4.22 mmol) was dissolved in 25 mL of H2O and
then added to the other flask. The solution was heated to 75 °C for 2 days. Upon
completion, the reaction was cooled to room temperature, and filtered over celite. The
filtrate was concentrated and dissolved with THF and EtOAc. The organic solutions
was washed 3x with 100 mL of saturated solution of NaHCO3 and 2x with 100 mL of
brine. The organic layers were isolated, dried over MgSO4, and concentrated to
dryness. The solid was then digested by stirring in chloroform for 1 hr. The solid was
filtered to obtain 1.3 (1.68 g, 35%) as a fine white powder. All spectral information
matched literature values.1

Compound 1.4: 3 propargyloxy-4-hydroxybenzaldehyde:

To a flame dried 3-neck flask, NaH (0.96 g, 40 mmol) was added, followed by the
addition of 20mL of DMSO in one portion, and was stirred until dissolved. 3,4dihydroxy benzaldehyde (2.76 g, 20 mmol) was then dissolved in DMSO (12 mL) and
was added all once at 0C. Once all aldehyde was added, the flask was removed from
the ice bath, and propargyl bromide (2.37g, 20mmole) was added drop wise by
syringe. The reaction was stirred overnight at room temperature. Reaction was poured
over ice and neutralized with 1M HCl and extracted with EtOAc (3 x 75 mL). Organic
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layers were washed with brine (3 x 50 mL), died over MgSO4, filtered, and the solvent
was removed under pressure. Flash chromatography to separated, using 20/80/1 of
ethyl acetate/hexane/ glacial acetic acid. Pure product, 1.4 (2.60 g, 74%) was isolated.
All spectral information matched literature values.1

Compound 1.5 propargyloxy-4-(2-bromoethoxy)benzaldehyde:

Added 1.4, propargyloxy-4-hydroxybenzaldehyde (1.65 g, 9.4 mmol), K2CO3 (6.00 g,
46.9 mmol), and DMF to a three neck flask. Reaction was stirred at room temperature
for 30 minutes. Dibromoethane (94 mmol, 6 mL) was then added in one portion and
heated overnight at 60 °C under N2 atmosphere. Mixture was poured over 350 mL of
water and was extracted using 3 x 10 mL (4 x 75mL) of ethyl acetate. Organic layers
were washed with NaOH 1M (2 x 75 mL), H2O (75 mL), then brine (3 x 75 mL).
Organic layer dried over MgSO4, filtered and solvent removed under vacuum. Using
hexanes and minimal ethyl acetate product was recrystallized to give 1.5 (2.06 g, 77%)
as a white solid. All spectral information matched literature values.1

Compound 1.6 [3 propargyloxy-4-(2-bromoethoxy)phenyl]methanol

To a three neck flask with N2 inlet, 1.5 (1.58 g, 5.60 mmol), was dissolved in
methanol/THF solvent. Solution was cooled to -9°C in (MeOH/ice) followed by
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addition NaBH4 (0.25g, 6.70mmole). Mixture was stirred at 0°C for 20 min then
allowed to warm to rt for an additional 40 min. Mixture was concentrated under
vacuum and then cooled to 0 °C and acidified with 150 mL of dilute HCl. Sample was
extracted with ethyl acetate (3 x 50 mL), then washed with brine (3 x 50 mL) and
dried over MgSO4. Sample was filtered, and concentrated in vacuum and purified
using recrystallization with hexanes to yield 1.6 (1.48g, 92%) as a white solid. All
spectral information matched literature values.1

Compound 1.7 [3 propargyloxy-4-(2-iodoethoxy)phenyl]methanol:

In a round bottom flask, sodium iodide (4.86 g, 32.46 mmol) and 1.6 (2.30 g, 8.11
mmol) were dissolved in acetone and refluxed overnight. Solvent was removed under
vacuum and solid was dissolved in DCM and subsequently washed with sodium
thiosulfate (2 x 50 mL), water (50 mL) and brine (2 x 50 mL). The organic layer was
dried over MgSO4, filtered and solvent was removed under vacuum to yield pure 1.7
(2.44 g, 98%) as a white solid. All spectral information matched literature values.1

Compound 1.8 [3-propargyloxy-4-(2-iodoethoxy)phenyl]methanol:
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In a three neck flask 1.7 (1.82 g, 5.48mmol) was dissolved in THF, to which DHP
(0.55 g, 6.58 mmol) was then added. In a separate flask PPTS (0.13 g, 0.54 mmol) was
dissolved in DCM and then added to main reaction flask. The reaction was stirred at
room temperature overnight. Upon completion the reaction was concentrated under
reduced pressure and subsequently diluted with EtOAc and washed with water and
brine. It was then dried over MgSO4, filtered and concentrated by vacuum. The crude
product was purified using flash chromatography with 20/80 EtOAc/Hexane. Product
isolated to yield 1.8 (2.08 g, 91%) as yellow oil. All spectral information matched
literature values.1

Compound 1.9

Cesium carbonate (1.27 g, 3.89 mmol) and 1.3 (0.26 g, 0.65 mmol) were added to a
dried three neck flask with a stir bar and purged with nitrogen. Dry DMF was then
added with a syringe and mixture was allowed to stir for 30 minutes at room
temperature. Then using minimal amounts of DMF, 1.8 was added (1.07 g, 2.59
mmol). The reaction was stirred under N2 at 65°C for 48 hours. Upon completion the
reaction was cooled to room temperature and was poured into 100 mL of water. The
aqueous layer was then extracted with 3 x 75 mL of EtOAc. Combined organic layers
were washed with 3 x 100 mL of brine. The organic layer was isolated, dried over
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MgSO4 and concentrated under vacuum. The crude product was purified by flash
chromatography using 50/50, 60/40, and 75/25 EtOAc/Hex. Product was isolated and
concentrated down to yield 1.9 (0.52 g, 63%). All spectral information matched
literature values.1

Compound 1.10 Tri-Propargyl Cryptophane A

To a round bottom containing methanol (165 mL), 1.9 (0.21 g, 0.16 mmol) dissolved
in DCM (5mL) was added. The reaction mixture was then cooled to 0°C and HClO4
(165 mL) is added in a drop-wise fashion. Reaction was stirred at room temperature
for 48 hrs. Upon completion the reaction was quenched with H2O (165 mL) and brine
(165 mL) and stirred for 1 hour. Half of the mixture was extracted with 4 x 100mL of
DCM, the organic layer is put aside and the second half of the reaction mixture was
extracted with 4x100mL of DCM. Organic layers were combined and washed with
H2O, saturated NaHCO3, and brine. Flash chromatography was performed using a
gradient of DCM/Acetone 2%-10% to afford pure 1.10 (0.054g, 34%) as a white solid.
All spectral information matched literature values.1

Compound 1.11: 2-(tritylthio)ethanamine
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To a round bottom containing thiol ethylamine (1 g, 8.8 mmol), TFA(6.3 mL) was
added followed by the addition of trityl chloride (2.45 g, 8.8 mmol) and stirred at
room temperature for three hours. The reaction was then concentrated, diluted with
EtOAC, washed with 3N NaOH (4 x 15 mL), H2O (15 mL), and saturated NaHCO3
(15 mL), and brine (15 mL). The organic layer was dried over MgSO4 and
concentrated down. The reaction was recrystallized using DCM and hexanes yielding
1.11 (2.68 g, 95%) as white solid. All spectral information matched literature values.2

Compound 1.12: 3-(azido)propionic acid

Bromopropionic acid (1.52 g, 10mmol) was dissolved in acetonitrile (20 mL) and to it
NaN3 (1.3 g, 20 mmol) was added. Reaction was refluxed overnight. Acetonitrile was
removed under vacuum and resulting solid was dissolved in EtOAc (100 mL), washed
with 0.1M HCl (3 x 60 mL), water (3 x 60 mL), and brine (100 mL). Organic layer
dried with MgSO4 and concentrated down yielding 3-(azido)propionic acid, 1.12
(0.50g, 43%) as a yellow oil. All spectral information matched literature values.3
Compound 1.13:

To a round bottom equipped with a stir bar, compounds 1.11 (1.16 g, 3.6 mmol), and
1.12 (0.38 g, 3.3 mmol) were added. Followed by the addition of HBTU (1.50 g, 3.96
mmol), round bottom was purged with N2 and then dry DCM (20 mL) was added
followed by DIPEA (1.2 mL, 6.6 mmol). Reaction was stirred at room temperature,
37

under N2 for two days. Upon completion the reaction was washed with NaHCO3 (50
mL) and brine (50 mL). Organic layer dried with MgSO4, filtered, and concentrated
down onto silica. The crude product was purified using a 20/80 - 70/30 solvent
gradient of EtOAC/Hex. The product was isolated and concentrated down to yield
1.13 (78%) as a white solid.
NMR (300 MHz, CDCl3): δ 7.46 – 7.35 (Ar CH, m, 6H), 7.33 – 7.27 (Ar CH, m,
6H), 7.25 – 7.19 (Ar CH m, 3H), 3.57 (COCH2, t, J = 6.5 Hz, 2H), 3.10 (-NHCH2, q, J
= 6.1 Hz, 2H), 2.44 ( -N3CH2-, t, J = 6.3 Hz, 2H), 2.32 (SCH2- ,t, J = 6.5 Hz, 2H).
13C NMR (75 MHz, CDCl ): δ 169.72, 144.65, 129.57, 128.06, 126.90, 66.90, 47.31,
3
38.35, 35.67, 31.87.
1H

Compound 1.14: Propionicthioacetate

Mercaptopropionic acid (1.4 mL 20mmol) was added to NaOH (2 M) at 0°C. Acetic
anhydride was then added and reaction was stirred for 30 minutes at 0°C. Reaction
was acidified to a pH ≈2 with 6N HCl. Then the mixture was extracted with EtOAc (3
x 30 mL). Organic layers were combined, dried with MgSO4, and concentrated down
reduced pressure to yield 1.14 (2.68 g, 91%) as white crystals. All spectral information
matched literature values.4
Compound 1.15: 2-azidoethylamine
Bromoethylamine (2.5 g, 12.20 mmol) was dissolved in 10 mL of water, followed by
the addition of NaN3 (2.38 g, 36.36 mmol) and was refluxed for 21 hrs. Reaction was
then cooled to 0°C and KOH (4g) was slowly added. The reaction mixture was then
extracted using diethyl ether (3 x 10 mL) and organic layers were collected, dried over
MgSO4 and concentrated until 10 mL was left (0.41g, 40%). All spectral information
matched literature values. 5
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Compound 1.16

To round bottom containing 1.15 (0.67 g, 4.5mmol) and 1.14 (0.43 g, 5.00 mmol)
were dissolved in DMF. EDC (2.96 g, 15.4 mmol) and HOBT (1.25 g, 8.19 mmol)
were then added and the reaction was stirred at room temperature for two days.
Reaction was diluted with water and extracted with DCM (3 x 50 mL). Organic layers
were then washed with brine, isolated, dried over MgSO4, filtered and concentrated
down. Purification was performed using flash chromatography (gradient of
EtOAc/Hexane) to give pure 1.16, (0.42g 44%) as a yellow oil.
NMR (300 MHz, CDCl3): δ 5.92 (NH, s, 1H), 3.38 (d, J = 3.9 Hz, 4H), 3.08 (t, J
= 7.0 Hz, 2H), 2.45 (t, J = 7.0 Hz, 2H), 2.27 (CH3-CO s, 3H).
13C NMR (75 MHz, CDCl ): δ 196.21, 170.95, 50.85, 38.97, 36.20, 30.61, 24.85.
3
1H

Compound 1.17

Tris (2 aminoethyl) amine (0.18 g, 1.3 mmol), phenylbenzylbromde (1.05 mL, 8.8
mmol), and K2CO3 (1.90 g, 13.8 mmol), were refluxed in CH3CN under N2 for 48 hrs.
Upon completion it was cooled on an ice bath and washed with acetonitrile, water,
methanol and then dissolved in hot toluene. Toluene washed with brine and dried over
MgSO4 and solvent was removed. Product was precipitated in methanol giving 1.17
(0.69 g, 77%) as a yellow oil. All spectral information matched literature values.6

Compound 1.18
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To a vial equipped with a stir bar, 1.10 (0.11 g, 0.11mmol) and 1.13 (0.14 g, 0.33
mmol) were dissolved in THF (5 mL). An aqueous solution of CuSO4 5H2O was
added, followed by the slow addition of a freshly prepared aqueous solution of sodium
ascorbic acid. Reaction was monitored by TLC (98%DCM/2%Acetone), upon
disappearance of 1.10, THF was removed under vacuum.
DCM and 3mL of concentrated NH3OH were added and stirred for 30 minutes. The
organic layer was then washed with water and brine, dried over MgSO4 and filtered.
Crude product was dried onto silica and purified using a 25 gram column (gradient of
2/98-20/80 acetone/DCM) on the combi-fash. Product was isolated to yield 1.18
(52%) as a white solid.
NMR (300 MHz, CDCl3): δ 7.72 (tetrazole CH, s, 3H), 7.42 – 7.36 (m, 20H), 7.30
– 7.19 (m, 32H), 6.81 (s, 3H), 6.77 (d, J = 1.4 Hz, 6H), 6.66 (s, 3H), 5.52 (-NH, t, J =
5.7 Hz, 3H), 5.15 – 4.98 (-OCH2C, m, 6H), 4.67 (-COCH2, t, J = 6.4 Hz, 6H), 4.53 (OCH2CH2O-, dd, J = 13.6, 6.3 Hz, 6H), 4.17 (-ArCH2, s, 12H), 3.56 (-OCH3, s, 9H),
3.37 (-OCH2CH2O-, dd, J = 14.2, 3.9 Hz, 6H), 3.03 (-NHCH2-, dt, J = 7.3, 3.6 Hz,
6H), 2.75 (-NCH2-, t, J = 6.4 Hz, 6H), 2.40 (-CH2S-, t, J = 6.3 Hz, 6H).
13C NMR (75 MHz, CDCl ): δ 168.85, 149.63, 148.37, 147.71, 146.52, 144.52,
3
134.06, 133.23, 131.63, 129.47, 128.01, 126.87, 123.98, 121.65, 120.72, 117.99,
114.46, 69.26, 66.93, 63.81, 56.03, 45.90, 38.33, 36.13, 31.64.
1H
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Compound 1.19

To a Shlenk tube equipped with a stir bar, 1.10 (61 mg, 0.064 mmol), 1.16 (41 mg,
0.19 mmol), and 1.17 (35 mg, 0.051 mmol) were added under N2 and dissolved in 2
mL of THF. In the glove box Cu(I)Br (7.3 mg, 0.051mmol) was added to the Shlenk
tube. The reaction was heated at 65°C for two days and monitored by TLC (2/98
acetone/DCM), upon disappearance of 1.10, the reaction was worked up by removing
THF under reduced pressure. Then DCM was added and the organic layer was washed
with water and brine, dried over MgSO4, filtered and then dried onto silica for
purification. Purified using 25 gram column and a gradient (2/98-20/80) of
acetone/DCM on combi-fash. The product was isolated to yield 1.19 (59%) as a white
solid.
NMR (300 MHz, CDCl3): δ 7.60 (s, 3H), 6.80 (s, 3H), 6.69 (d, J = 13.4 Hz, 6H),
6.59 (s, 3H), 6.12 (s, 2H), 5.15 – 5.00 (m, 6H), 4.49 (q, J = 6.7, 6.3 Hz, 12H), 4.12 (s,
12H), 3.75 (d, J = 5.6 Hz, 6H), 3.56 (-OCH3, s, 9H), 3.32 (d, J = 13.7 Hz, 6H), 3.06 (t,
J = 7.0 Hz, 7H), 2.42 (t, J = 6.9 Hz, 6H), 2.25 (-COCH3, s, 9H).
13C NMR (75 MHz, CDCl ): δ 196.01, 171.30, 149.56, 148.29, 147.77, 146.45,
3
134.10, 133.37, 131.68, 129.57, 123.70, 121.40, 120.58, 114.41, 69.20, 63.93, 56.07,
49.71, 39.46, 36.11, 30.63, 24.76.
1H
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Compound 1.20: AuNPs
Gold nanoparticles were synthesized with dodecanethiol capping ligands using
the Brust-Schiffrin “two-phase” method.7 An aqueous solution of HAuCl4 H2O (0.10
g, 0.30 mmol) was mixed with tetraoctylammonium bromide (0.71 g, 1.31 mmol) in
toluene. The solution was stirred vigorously until all of the gold was transferred into
the organic layer. Dodecanethiol (0.055g, 0.27 mmol) was then added and stirred for
20 mins, at which point the solution turned clear. An aqueous solution of NaBH4 (0.12
g. 3.24 mmol) was slowly added and the resulting solution turned brown. The reaction
was then stirred for 3 hrs at room temperature. The organic phase was then isolated
and concentrated down to ~5 mL, which was then mixed with 200 mL of EtOH and
kept at -18° C for 4 hours. The dark brown precipitate was then filtered off and redissolved in 5 mL of toluene, which was then precipitated again using 100 mL EtOH.
The suspension was then filtered and washed with copious amounts of EtOH to
remove any free dodecane thiol, product was dried under vacuum overnight.
Transmission electron miscopy validated the presence of AuNPs.

Compound 1.21: Azide-AuNPs
The 11-bomoundecylthioacetate (0.10 g, 0.32 mmol) was dissolved in 1 mL of
ethanol. NaOH was added (0.1 mL) and reaction mixture was refluxed for 2 hrs. The
reaction was then neutralized with 6 mL of 2 M HCl. The mixture was transferred to
separatory funnel and then 10 mL of diethyl ether was added followed by the addition
of with 5 mL of H2O. The organic layer was washed with 5 mL of H2O, isolated, dried
of MgSO4 and then filter. The solvent was removed and product was left to dry under
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vacuum overnight. The deprotected 11-bomoundecylthiol was then dissolved in DCM
and added to AuNPs. AuNPs functionalized with 11-bromoundecylthiol (28 mg) were
dissolved in DCM (6 mL) and added to a solution of sodium azide (70 mg) in DMSO
(6 mL). The solution was stirred for 2 days at room temperature. An IR was taken to
verify the presence of an azide and once complete water was added and the organic
layer was isolated. The AuNPs were washed with ethanol and then dried under
vacuum to yield AuNPs-N3 (0.021 g). FTIR: 2094.06 cm-1

1H

NMR spectra of compound 1.13

13C

NMR spectra of compound 1.13
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1H

NMR spectra of compound 1.16
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13C

NMR spectra of compound 1.16
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1H

NMR spectra of compound 1.18
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13C

NMR spectra of compound 1.18
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COSY of 1.18

48

HMQC of Compound 1.18

49

50

1H

NMR spectra of compound 1.19
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52

Transmission Electron Microscopy (TEM) images of 1.20
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Transmission Electron Microscopy (TEM) images of 1.20
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MANUSCRIPT 2

Vanadium Catalyzed Oxidative Coupling of sp3 C-H Bonds to Heteroarenes
Abstract
The vanadium-catalyzed oxidative coupling of substituted 2-phenylimidiazo[1,2-a]pyridines to N-methylmorpholine which acts as the sacrificial oxidant
has been achieved. This reaction was applied to various 2-phenyl-imidiazo[1,2a]pyridines substrates resulting in yields as high as 90%.
Introduction
Incorporating new carbon–carbon and carbon–nitrogen bonds into organic
molecules is an apparent need in today’s chemical industry. There have been many
recent advances in this field, most using metal catalysis, however most require prefunctionalization steps and have poor atom economy.1 The ability to oxidatively couple
two carbon hydrogen bonds (or carbon–hydrogen and nitrogen –hydrogen) to form a
carbon-carbon bond (or carbon–nitrogen bond) with no pre-functionalization would be
ideal.2

Incorporating C–N bonds via cross dehydrogenative coupling can be

accomplished through direct oxidative amination or oxidative aminomethylation. The
direct formation of C–N bonds under oxidative conditions has been achieved through
various methods.3 Ami-nomethylation is an alternative and convenient way to incorporate C–N bonds (Scheme 1). The less common oxidative aminomethylation is shown
by Uang et al., who achieved oxidative aminomethylation of naphthalenes.5 Another
example of aminomethylation is shown by Mitchel et al., who developed a method for
installing N-methylmorpholine on imidazopyridines structures, a precursor to an active
57

pharmaceutical ingredient that could serve as a treatment of several myeloproliferative
disorders.10

Scheme 1- Amination vs Aminomethylation

There are numerous methods to oxidatively couple two sp2 hybridized carbons
in high yields.2 The coupling of an sp3 to an sp2 hybridized carbon is much less common
due to the less reactive nature of sp3 hybridized C–H bonds compared to that of sp2 ¬C–
H bonds.4 In order to achieve sp3 C–H bond activation, reactive directing groups are
often needed.3 Another difficulty is the potential for β-hydride elimination after C–H
activation of sp3 bonds.4 The oxidative coupling of a sp3 C–H bond to a sp2 C–H bond
has received little attention,4,5,6,7 so there is still a great need to invent new ways of
oxidatevly coupling sp3- sp2 carbon bonds in an efficient and green way.
Pharmaceuticals such as necopidem, saripidem, and zolpidem contain a
substituted imidazo[1,2-a]pyridines back bone (Figure 1).8 Providing a way to
oxidatively couple the 3 position of 2-phenyl-imidazo[1,2-a]pyridine with alkyl
derivatives would be a useful tool to have when synthesizing pharmaceuticals. This
paper proposes a vanadium catalyzed oxidative coupling of imidazopyridines with Nmethylmorpholine oxide which serves as both sp3 hybridized coupling partner and the
sacrificial oxidant. Using these conditions we were able to perform oxidative
aminomethylation of imidazopyridines.
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Figure 1: Pharmaceuticals with imidazo[1,2-a]pyridines backbones

The synthesis of the starting material is accomplished in one step via an
imminium formation followed by a nucleophlic cyclization (Scheme 2).9 The nature of
the substituents on pyridine or bromoacetophenone did not greatly affect the starting
material yields 1.

Scheme 2: Synthesis of Starting Material

Results and Discussion
In order to achieve optimum conditions we screened solvent, catalys, catalyst
loading, time, and equivalents of NMO. Ethanol, toluene, and tetrahydrofuran were
initially tested as alternative solvents (Table 1 entries 4, 5, and 6). Nevertheless, none
had comparable yields to methylene chloride. The mole percent of vanadium (III)
acetylacetonate, VO(acac)2 was varied from 25% to 10%, showing that lower catalyst
loading provided minimal impurities. To ensure that VO(acac)2 was the ideal catalyst
to use we tested V2O5 ( entries 9,10.16 and 17). While it eliminated the formation of the
impurity, 3, it required longer reaction times and low amounts of NMO (entry 16),
which still did not result in comparable yields to when VO(acac)2 was used under the
same conditions (entry 14) . The best yield was achieved using 10% of
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entry

VO(acac)2
Mol%

NMO

Solvent

Time
(hrs)

Product
a
Yield

3

1

25

10

DCM

18

59

3.7

2

10

10

DCM

18

68

0.3

3

20

10

DCM

18

62

2.7

4

20

10

Ethanol

18

33

1.5

5

20

10

Toluene

18

30

28.5

6

20

10

THF

18

57

1.3

7

20

10

DCM

18

68

2.2

8

20

5

DCM

18

68

10.7

9

20

b

5

DCM

5

58

15

10

20

b

5

DCM

4

31

14.9

11

10

5

DCM

18

72

4.6

12

10

5

DCM

6

88

5.8

13

20

5

Dioxane

12

80c

0

14

20

3

DCM

18

69

18.7
--

3

DCM

4

incomplete
conversion

20

b

3

DCM

18

57

0

17

20

b

1.2

DCM

18

36

5

18

20

1

DCM

18

52

34.2

15
16

20

(a) Product yield determined by NMR (b) V2O-5 used as catalyst (c) Actual yield

Table 1- Optimization of the Reaction Conditions

(VO(acac)2), 5 equivalents of NMO for 6 hours in methylene chloride (entry 12).
However by changing the solvent from methylene chloride to 1,4 - dioxane and
increasing the catalyst loading VO(acac)2, we were able to avoid any of 3 from forming
and achieve an 80% yield. Performing a GC time study gave further insight into when
the reaction would produce the least impurity (see Chart 1). The starting material was
always present in small amounts as was 3. We stopped the reaction at 12 hours despite
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the presence of starting material to avoid product decomposition. As such we decided
to perform our substrate scope using entry 13 as our optimized conditions.
Performing this reaction using substrates with electron withdrawing groups on
the para position of the phenyl substituent resulted in less favorable yields or did not
react. While electron donating groups in the para position lead to higher yields. Looking
at the substrate scope (table 2) entry 10 has a nitro substituent in the para position
resulted in no product while entry 8 with an ether substituent in the same position gave
us an 84% yield. The addition of a second electron donating substituent led to lower
yields than only one electron donating group (4). Changing the position of the methyl
group at C6 (entry 6) as to C8 (entry 7) gave a slightly higher yield. Yields varied with
different halogens substituted at the phenyl para position. For instance, a chlorine
substituted phenyl ring had a much higher yield than when a bromine or fluorine was
substituted in the same position. The addition of a methyl group at C7 on the Br para
substituted ring gave a lower yield then fluorine. Methyl groups at the C6 position for
both fluorine and chlorine substituted rings had high yields.
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Table 2: Substrate Scope

Previous studies of vanadium oxidative coupling of structures similar to 1
propose a radical mechanism,10 while others theorize product is formed by way of a
62

Mannich-type reaction.5 We propose a Mannich type mechanism is responsible for the
formation of our product (Scheme 4). This was determined by running a Mannich
reaction using 1, formaldehyde, and morpholine to make the imminium in situ resulting
in yields up to 98% (scheme 3). Running our normal reaction conditions in the presence
of TEMPO, a radical inhibitor, did not prevent product from forming further proving
this reaction a Mannich-type mechanism is responsible.

Scheme 3-Pure Mannich Conditions

As such we believe the product is formed by the following mechanism (scheme
4). The N- methyl morpholine oxidizes the VO(acac)2 catalyst resulting in the formation
of the imminium ion. The vanadium species extracts a proton from 1 which then attacks
the immionium ion forming our product 2. The elimination of water from vanadium
regenerates the catalyst. We believe the main impurity is formed when the imminiom
reacts with one of the ligands from the vanadium catalyst.
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Scheme 4- Proposed mechanism of product and impurity

Conclusions
The vanadium cataylzed oxidative coupling of substituted imidazole pyridines
to nmethylmorpholene was achieved in yields up to 90%. Despite the ability to
produce this product using true mannich conditions we believe this to useful method to
demonstrate oxidative coupling.
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Experimental Section

Reagents
All substrates were purchased from Sigma Aldrich and Fisher Scientific. Flash
chromatography was performed using Teledyne ISCO CombiFlashRf Apparatus using
RediSep Rf Silica gel (60 Angstroms, 40-60 microns).
Instrumentation
GC/MS analysis was carried out on an Agilent Technologies 6890 GC system fixed
with a 5973 mass selective detector]. NMR spectra were acquired with a Bruker
Avance III 300 MHz spectrometer.

General Synthesis of 2-phenyl- Imidazo[ 1,2-a] pyridines:
67

2-amino pyridine (1.3 g 13.8 mmol), 1-bromoacetophenone (2.19 g, 11.1 mmol),
sodium bicarbonate (1.45 g, 17.25 mmol) and ethanol (9 ml) were added to a flask. A
stir bar was added and the reaction was stirred at 60°C for 4hrs. The reaction was
monitored by TLC at a 50:50 ethyl acetate: hexanes solvent system. After reaction was
completed, the ethanol was rotavapped off, and 50mL of water was added in portions
to dissolve the solid. The water was then extracted with two 50mL portions of ethyl
acetate and dried with sodium sulfate. The filtrate was rotavapped off. A column was
ran (80 g column on a gradient) to yield 1.66 g (78%) of product. All spectral
information matched literature values.1
Representative Procedure for Synthesis of substituted imidazole pyridines with
N- methylmorpholene
Imidazo[1,2-a]pyridine (1 mmol), NMO (5 mmol), VO(acac)2 (20 mol%), were
dissolved in 1,4-dioxane (4 mL), and refluxed for 12 hrs. Upon completion the
reaction was evaporated and diluted with water (10mL) and extracted with EtOAc
(2x10mL). Organic layers were dried of Na2SO4 and concentrated. Purified by column
chromatography using 4/1 EtOAc:Hex.
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Characterization of Compounds:
Characterization of Compound 2

NMR (300 MHz, CDCl3): δ 8.43 (dd), 7.80 (m), 7.64(dt,), 7.46(m), 7.38 (m), 7.22
(ddd), 3.98 (s), 3.67(t), 2.48 (t)
13C NMR (101 MHz, CDCl ): δ 145.35, 145.10, 134.46, 128.87, 128.44, 127.74,
3
125.29, 124.53, 117.29, 115.88, 111.85, 66.98, 53.19, 52.12.
LRMS EI (m/z): [M+] calc’d for C18H19N3O 293.15, observed 293.10
1H
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Spectroscopic Data for Novel Compounds in Table 3:
Characterization of Compound 3.4

NMR (400 MHz, CDCl3): δ 8.42 (d,J =6.9 Hz, 1H) 7.70 (d, J=8.39 Hz, 2H),
7.63(d, J=9.2hz, 1H), 7.27(d, J= 7.9 Hz, 2H), 7.24 – 7.17 (m, 1H), 6.82(t J=6.4 Hz,
1H), 3.96(s, 2H), 3.67 (t, J=4.6 Hz, 4H), 2.48 (t, J=4.6Hz, 4H), 2.41 (s, 3H)
13C NMR (101 MHz, CDCl ) δ 145.40, 145.04, 137.51, 131.55, 129.17, 128.17,
3
125.24, 124.41, 117.20, 115.61, 111.75, 66.99, 53.19, 52.16, 21.28.
LRMS EI (m/z): [M+] calc’d for C19H21N3O 307.17, observed 307.20
1H
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Characterization of Compound 3.5

NMR (400 MHz, CDCl3): δ 8.51 (s, 1H), 7.69 (d, J= 8.0, 2H ), 7.53 (d, J=9.0,
1H), 7.26 (d, J = 7.4, 2H), 7.06 (d, J = 9.3,1H), 3.93 (s, 2H), 3.67 (t, J=4.4 , 4H), 2.48
(t, J=4.4, 4H), 2.40 (s, 3H), 2.37 (s,3H)
13C NMR (101 MHz, CDCl ): 145.23, 144.10, 137.35, 131.73, 129.13, 128.66, 127.53,
3
1H

122.72, 121.31, 116.53, 115.36, 67.02, 53.20, 52.10, 21.27, 18.53.

LRMS EI (m/z): [M+] calc’d for C20H23N3O 321.18, observed 321.20
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Characterization of Compound 3.6

NMR (300 MHz, CDCl3): δ 8.15, (s, 1H), 7.75 (d, J=8.72 Hz, 2H), 7.53 (d, J=
9.55 Hz 1H), 7.08 (d, J=9.45 Hz, 1H), 7.00 (d, J=8.86 Hz, 2H), 3.92 (s,2H), 3.87 (s,
3H), 3.69 (t, J= 4.47 Hz, 4H), 2.49 (t, J =4.49 Hz ,4H), 2.38 (s, 3H)
13C NMR (75 MHz, CDCl3): δ 159.36, 143.87, 130.03, 127.84, 122.70, 121.59,
121.00, 120.32, 116.35, 115.06, 113.93, 77.44, 67.01, 55.31, 53.20, 52.07, 18.54.
LRMS EI (m/z): [M+] calc’d for C20H23N3O2 337.18, observed 337.20
1H
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Characterization of Compound 3.7

NMR (400 MHz, CDCl3): δ 8.15 (s, 1H), 7.55 (d, J=9.2 Hz 1H), 7.33 – 7.41 (m,
3H), 7.07 (d, J =9.2 Hz 1H), 6.92 (d, J = 7.5 1H), 3.94 (s, 2H), 3.88 (s, 3H), 3.68 (t, J =
4.4 Hz, 4H), 2.50 (t, 4H), 2.38 (s, 3H)
13C NMR (101 MHz, CDCl ): δ 159.67, 145.09, 144.10, 135.99, 129.36, 127.68,
3
122.66, 121.49, 121.24, 116.65, 115.74, 113.86, 67.01, 55.34, 53.20, 52.01, 18.54.
LRMS EI (m/z): [M+] calc’d for C20H23N3O2 337.18, observed 337.20
1H
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Characterization of Compound 3.8

NMR (300 MHz, CDCl3): δ 8.13 (s, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.49 (s, 1H),
7.37 (d, J = 8.3, 1H), 7.08 (d, J = 9.6 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 3.98 (s, 3H),
3.94 (s, 3H), 3.70 (t, J = 4.4 Hz, 4H), 2.52 (t, J = 4.5 Hz, 4H), 2.39 (s, 3H).
13C NMR (75 MHz, CDCl ): δ 148.95, 148.76, 145.01, 143.95, 127.72, 127.32,
3
122.47, 121.58, 121.11, 116.44, 115.19, 112.02, 110.95, 67.02, 55.99, 55.91, 53.23,
52.04, 18.55.
LRMS EI (m/z): [M+] calc’d for C21H25N3O3 367.19, observed 368.0
1H
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Characterization of Compound 3.9

NMR (300 MHz, CDCl3): δ 8.27 (d, J = 6.8 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H),
7.39 – 7.29 (m, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.96 (d, J = 8.3 Hz, 7.6 Hz, 1H), 6.76 (t,
J = 6.8 Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.93 (s, 2H), 3.68 (t, J = 4.5 Hz, 4H), 2.67
(s, 3H), 2.50 (t, J = 4.5 Hz, 3H).
13C NMR (75 MHz, CDCl ) δ 148.95, 148.81, 145.27, 144.77, 127.34, 127.05,
3
123.51, 122.82, 121.43, 115.83, 112.37, 112.03, 111.02, 67.01, 55.97, 55.94, 53.22,
52.16, 17.18.
LRMS EI (m/z): [M+] calc’d for C21H25N3O3 367.19, observed 367.20
1H
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Characterization of Compound 3.10

NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.1 Hz, 1H), 7.81 – 7.74 (m, 2H), 7.64 (d,
J = 9.06 Hz, 1H), 7.22 (t, J = 6.7Hz, 1H), 7.11 (m, 2H), 6.83 (t, J = 6.7 Hz, 1H), 3.93
(s, 2H), 3.67 (t, J = 4.4 Hz, 4H), 2.47 (t, J = 4.4 Hz, 4H).
13C NMR (101 MHz, CDCl ): δ 162.57 (J
3
CF = 253 Hz), 145.07, 144.48, 130.63,
130.53 (JCF = 9 Hz), 125.18, 124.67, 117.28, 115.42 (JCF 21 Hz), 115.32, 111.98,
66.96, 53.20, 52.05.
LRMS EI (m/z): [M+] calc’d for C18H18FN3O 311.14, observed 311.10
1H
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Characterization of Compound 3.11

NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 7.81 – 7.74 (m, 2H), 7.51 (d, J = 9.2 Hz,
1H), 7.16 – 7.09 (m, 2H), 7.06 (dd, J = 9.2, 1.7 Hz, 1H), 3.88 (s, 2H), 3.66 (t, J = 4.6
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H), 2.36 (s, 3H).
13C NMR (101 MHz, CDCl ): δ 162.50 (J
3
CF = 245 Hz), 161.28, 144.32, 144.13,
130.45 (JCF = 8 Hz), 127.79, 122.64, 121.57, 116.61, 115.51, 115.37 (JCF = 21 Hz),
66.98, 53.20, 51.98, 18.53.
LRMS EI (m/z): [M+] calc’d for C19H20FN3O 325.16, observed 325.20
1H
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Characterization of Compound 3.12

NMR (400 MHz, CDCl3): δ 8.27 (d, J = 6.9 Hz, 1H), 7.80 – 7.72 (m, 2H), 7.36 (s,
1H), 7.18 – 7.08 (m, 2H), 6.66 (dd, J = 7.1, 1.7 Hz, 1H), 3.89 (s, 2H), 3.65 (t, J = 4.6
Hz, 4H), 2.45 (t, J = 4.4, 4H), 2.40 (s, 3H).
13C NMR (101 MHz, CDCl ): δ162.4 (J
3
CF = 250 Hz), 161.28, 145.49, 144.11, 135.64,
130.45 (JCF = 9 Hz), 124.37, 115.55 (JCF = 20 Hz), 115.16, 115.26, 114.62, 66.97,
53.17, 52.04, 21.34.
LRMS EI (m/z): [M+] calc’d for C19H20FN3O 325.16, observed 325.20
1H
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Characterization of Compound 3.13

NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.0, 1.2 Hz, 1H), 7.78 – 7.72 (m, 2H),
7.62 (d, J = 9.0Hz, 1H), 7.45 – 7.39 (m, 2H), 7.22 (ddd, J = 9.2, 6.7, 1.3 Hz, 1H), 6.83
(t, J = 6.9 Hz, 1H), 3.93 (s, 2H), 3.66 (t, J = 4.6 Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H).
13C NMR (101 MHz, CDCl ) δ 145.13, 144.18, 133.74, 133.00, 130.06, 128.67,
3
125.18, 124.77, 117.33, 116.07, 112.05, 66.93, 53.19, 52.02.
LRMS EI (m/z): [M+] calc’d for C18H18ClN3O 327.11, observed 327.10
1H
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Characterization of Compound 3.14

NMR (400 MHz, CDCl3): δ 8.14 (s, 1H), 7.78 – 7.74 (m, 2H), 7.52 (d, J = 9.2 Hz,
1H), 7.43 – 7.38 (m, 2H) 7.07 (dd, J = 9.1, 1.7 Hz, 1H), 3.89 (s, 2H), 3.66 (t, J= 4.6
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4 H), 2.36 (s, 3H)
13C NMR (101 MHz, CDCl ) δ 144.21, 144.03, 133.58, 133.20, 130.00, 128.61,
3
127.90, 122.62, 121.67, 116.67, 115.82, 66.96, 53.19, 51.96, 18.54.
LRMS EI (m/z): [M+] calc’d for C19H20ClN3O 341.13, 342.0
1H
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Characterization of Compound 3.15

NMR (400 MHz, CDCl3): δ 8.58 (s, 1H), 7.74 – 7.69 (m, 2H), 7.52 (d, J = 9.5 Hz,
1H), 7.45 – 7.41 (m, 2H), 7.29 (dd, J = 9.5, 1.9 Hz, 1H), 3.92 (s, 2H), 3.68 (t, J = 4.6
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H).
13C NMR (101 MHz, CDCl ): δ 144.94, 143.56, 134.11, 132.45, 130.03, 128.78,
3
128.22, 125.38, 117.96, 116.48, 106.73, 66.89, 53.21, 52.04.
LRMS EI (m/z): [M+] calc’d for C18H17BrClN3O 405.02, 407.00
1H
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Characterization of Compound 3.16

NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.0 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.62 (d,
J = 9.1 Hz, 1H), 7.59 – 7.55 (m, 2H), 7.25 – 7.20 (m, 1H), 3.93 (s, 2H), 3.66 (t, J = 4.6
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H).
13C NMR (101 MHz, CDCl ): δ 145.15, 144.19, 133.45, 131.62, 130.36, 125.18,
3
124.80, 122.00, 117.35, 116.10, 112.07, 66.93, 53.19, 52.03.
LRMS EI (m/z): [M+] calc’d for C18H18BrN3O 371.06, observed 371.10
1H
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Characterization of Compound 3.17

NMR (300 MHz, CDCl3): δ 8.28 (d, J = 7.1 Hz, 1H), 7.69 (d, J = 8.6 Hz, 2H),
7.58 (d, J = 8.5 Hz, 2H), 7.38 (s, 1H), 6.68 (d, J = 6.7 Hz, 1H), 3.91 (s, 2H), 3.67 (t, J
= 4.6 Hz, 4H), 2.47 (t, J = 4.6 Hz, 4H), 2.43 (s, 3H).
13C NMR (101 MHz, CDCl ): δ 145.60, 143.86, 135.79, 133.63, 131.58, 130.31,
3
124.38, 121.84, 115.71, 115.52, 114.73, 66.97, 53.17, 52.03, 21.38.
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O 385.08, observed 385.10
1H
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Characterization of Compound 3.18

NMR (400 MHz, CDCl3): δ 8.59 (s, 1H), 7.69 – 7.64 (m, 2H), 7.62 – 7.57 (m,
2H), 7.53 (dd, J = 9.5, 0.8 Hz, 1H), 7.29 (dd, J = 9.5, 1.9 Hz, 1H), 3.93 (s, 2H), 3.69
(t, J = 4.5 Hz, 4H), 2.47 (t, J = 4.5 Hz, 4H).
13C NMR (101 MHz, CDCl ): δ 144.93, 143.56, 132.89, 131.72, 130.31, 128.24,
3
125.37, 122.35, 117.95, 116.49, 106.75, 66.88, 53.20, 52.02.
LRMS EI (m/z): [M+] calc’d for C18H17Br2N3O 448.97, observed 451.00
1H
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Characterization of Compound 3.19

NMR (400 MHz, CDCl3):) δ 8.59 (s, 1H), 7.71 – 7.61 (m, 2H), 7.52 (d, J = 9.5,
1H), 7.33 – 7.19 (m, 3H), 3.95 (s, 2H), 3.68 (t, J = 4.6 Hz, 4H), 2.46 (s, 4H), 2.41 (s,
3H).
13C NMR (101 MHz, CDCl ): δ 146.18, 143.46, 137.86, 131.02, 129.26, 128.67,
3
127.77, 125.41, 117.81, 116.06, 106.37, 66.93, 53.19, 52.15, 21.29.
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O 385.08, observed 385.10
1H
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Characterization of Compound 3.21

NMR (400 MHz, CDCl3): δ 8.57 (s, 1H), 7.73 – 7.67 (m, 2H), 7.51 (d, J = 9.4 Hz,
1H), 7.28 – 7.24 (m, 1H), 7.03 – 6.96 (m, 2H), 3.94 (s, 2H), 3.86 (s, 3H), 3.69 (t, J =
4.6 Hz, 4H), 2.47 (t, J = 4.6 Hz, 4H).
13C NMR (101 MHz, CDCl ) δ 159.54 , 145.98 , 143.41 , 130.00 , 127.71 , 126.45 ,
3
125.31 , 117.71 , 115.73, 113.99 , 106.31 , 66.93 , 55.30 , 53.20 , 52.15 .
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O2 401.07, observed 403.10
1H
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Characterization of Compound 3.22

NMR (400 MHz, CDCl3): δ 8.90 (s, 1H), 8.27 (d, J =7.6 Hz, 1H), 8.22 (d. J = 6.9
Hz, 1H) , 8.19 (d, J = 8.39, 1H ) 7.61 (t, J = 8.0 Hz, 1H), 7.04 (d, J = 6.8, 1H), 6.79 (t,
J = 6.9 Hz, 1H), 3.91 (s, 2H), 3.70 (t, J = 4.6 Hz, 4H), 2.65(s, 3H), 2.52 (t, J = 4.6 Hz,
4H).
13C NMR (101 MHz, CDCl ) δ 148.44 , 145.67, 142.39, 136.60 , 134.65 , 129.37 ,
3
127.64 , 123.88 , 123.79 , 122.43 , 122.24 , 117.55 , 112.60 , 66.91 , 53.11 , 51.75 ,
17.05 .
LRMS EI (m/z): [M+] calc’d for C19H20N4O3 352.15, observed 352.20
1H
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